Article Text

Download PDFPDF
A Standardized Anesthetic and Surgical Clinical Pathway for Esophageal Resection: Impact on Length of Stay and Major Outcomes
  1. Grete H. Porteous, MD*,
  2. Joseph M. Neal, MD*,
  3. April Slee, MS,
  4. Henner Schmidt, MD and
  5. Donald E. Low, MD
  1. *Department of Anesthesiology, Virginia Mason Medical Center
  2. †Axio Research
  3. Department of General Thoracic Surgery, Virginia Mason Medical Center, Seattle, WA
  1. Address correspondence to: Grete H. Porteous, MD, 1100 Ninth Ave (B2-AN), Seattle, WA 98101 (e-mail: Grete.Porteous{at}vmmc.org).

Abstract

Background and Objectives Esophageal cancer is a leading cause of cancer death worldwide, and esophageal resection is associated with extremely high perioperative morbidity and mortality. A perioperative clinical pathway for esophagectomy patients in which anesthetic care is both integral and standardized has not been described previously.

Methods A continuously refined clinical pathway for perioperative care of the esophagectomy patient has been developed at the Virginia Mason Medical Center over the past 22 years. Ongoing data collection records patient demographics, comorbidities, tumor stage, and various outcomes including intensive care unit and hospital length of stay, surgical complications, and morbidity and mortality rates.

Results Over time, patients presenting for surgical treatment of esophageal cancer have had significantly higher Charlson comorbidity scores and a higher incidence of diabetes mellitus, hypertension, liver disease, and history of deep vein thrombosis or pulmonary embolism. During the same period, intensive care unit and hospital length of stays have decreased, whereas most complication rates have remained stable despite more advanced tumor stage and increased use of neoadjuvant chemoradiotherapy. In-hospital and 30-day mortality rates are well below national averages at 0.5% each.

Conclusions We present a detailed anesthetic and surgical perioperative pathway for esophageal resection, along with evidence of improved or stable patient outcomes despite an increase in comorbidity burden and increasingly advanced tumor stage.

Statistics from Altmetric.com

Footnotes

  • This work was not supported by any external funding sources.

    The authors declare no conflict of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.